Yogesh Jeelall
Australian National University
16 Papers
7 Citations
Yogesh Jeelall is an academic researcher from Australian National University. The author has contributed to research in topics: B cell & Diffuse large B-cell lymphoma. The author has an hindex of 10, co-authored 15 publications. Previous affiliations of Yogesh Jeelall include University of Western Australia & Harry Perkins Institute of Medical Research.
Chat about Author
Papers
Toll-Like Receptors and Cancer: MYD88 Mutation and Inflammation
TL;DR: The need for a better understanding of TLRs in cancers and the development of novel anti-cancer therapies targeting TLRs is highlighted, and how mutations can hijack the TLR signaling pathways to give rise to cancer is discussed.
Consequences of the recurrent MYD88 L265P somatic mutation for B cell tolerance
TL;DR: B cells expressing the MYD88 L265P mutation undergo rapid TLR ligand-independent proliferation that is self-limiting unless apoptosis is opposed.
The revolving door: antibiotic allergy labelling in a tertiary care centre
Brittany Knezevic,Dustin Sprigg,Jason Seet,Michelle Trevenen,Michelle Trevenen,Jason A Trubiano,William B Smith,Yogesh Jeelall,Sandra Vale,Richard Loh,Andrew McLean-Tooke,Michael Lucas +11 more
TL;DR: Patients frequently report antibiotic allergies; however, only 10% of labelled patients have a true allergy, and it is unlikely that they have atrue allergy.
Denisovan, modern human and mouse TNFAIP3 alleles tune A20 phosphorylation and immunity.
Nathan W. Zammit,Nathan W. Zammit,Owen M. Siggs,Owen M. Siggs,Paul Gray,Keisuke Horikawa,David B. Langley,David B. Langley,Stacey N. Walters,Stacey N. Walters,Stephen R. Daley,Stephen R. Daley,Claudia Loetsch,Joanna Warren,Joanna Warren,Jin Yan Yap,Daniele Cultrone,Daniele Cultrone,Amanda J. Russell,Elisabeth K. Malle,Jeanette E. Villanueva,Mark J. Cowley,Mark J. Cowley,Velimir Gayevskiy,Marcel E. Dinger,Marcel E. Dinger,Robert Brink,Robert Brink,David Zahra,David Zahra,Geeta Chaudhri,Gunasegaran Karupiah,Gunasegaran Karupiah,Belinda Whittle,Carla M. Roots,Edward M. Bertram,Michiko Yamada,Yogesh Jeelall,Anselm Enders,Benjamin E. Clifton,Peter D. Mabbitt,Colin J. Jackson,Susan R. Watson,Craig N. Jenne,Craig N. Jenne,Lewis L. Lanier,Tim Wiltshire,Matthew H. Spitzer,Matthew H. Spitzer,Garry P. Nolan,Frank Schmitz,Frank Schmitz,Alan Aderem,Benjamin T. Porebski,Ashley M. Buckle,Derek W. Abbott,John B. Ziegler,Maria E. Craig,Maria E. Craig,Paul Z. Benitez-Aguirre,Juliana Teo,Stuart G. Tangye,Stuart G. Tangye,Cecile King,Cecile King,Melanie Wong,Murray P. Cox,Wilson Phung,Jia Tang,Wendy Sandoval,Ingrid E. Wertz,Daniel Christ,Daniel Christ,Christopher C. Goodnow,Christopher C. Goodnow,Shane T. Grey,Shane T. Grey +76 more
TL;DR: Genetic analyses of anatomically modern humans, extinct Denisovan hominins and mice revealed a TNFAIP3 allelic series with alterations in the encoded immune response inhibitor A20, which lower A20 activity and increase autoinflammatory responses.
64
Synergistic cooperation and crosstalk between MYD88 L265P and mutations that dysregulate CD79B and surface IgM.
James Q. Wang,Yogesh Jeelall,Peter Humburg,Emma L Batchelor,Sarp M Kaya,Hee Min Yoo,Christopher C. Goodnow,Keisuke Horikawa +7 more
TL;DR: It is revealed that CD79B and surface IgM constitute a rate-limiting checkpoint against B cell dysregulation by MyD88L265P and provide an explanation for the co-occurrence of MYD88 andCD79B mutations in lymphomas.